Recertification (MOC) Review Course Webcast (2015): Infections

Overview

The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically-specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam. Sample multiple choice practice questions as well as case based discussions and debates will be utilized to prepare attendees for the upcoming Recertification Examination.

Target Audience

  • Urologist

Learning Objectives

Upon completion of this course, participants should be able to:

  1. Review generally accepted urological practices for superior patient care.
  2. Develop a core knowledge of urology necessary for taking the Recertification Examination.
  3. Examine the most recent changes and additions to the AUA guidelines
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
09/26/2015
Course expires: 
09/26/2018
Part of: 
Recertification (MOC) Review Course Webcast (2015)
Rating: 
0

Faculty Disclosures
Mohamad Ezzedine Allaf, MD: Nothing to disclose
Bernard H. Bochner, MD, FACS: Nothing to disclose
Steven Benjamin Brandes, MD: Allergan: Scientific Study or Trial; American Medical Systems: Meeting Participant or Lecturer; Astellas: Meeting Participant or Lecturer
Mantu Gupta, MD: Cook Urological: Meeting Participant or Lecturer; Boston Scientific: Meeting Participant or Lecturer
C.D. Anthony Herndon, MD, FAAP, FAC: Nothing to disclose
Badrinath R. Konety, MD: Amgen: Meeting Participant or Lecturer; Axogen Inc.: Consultant or Advisor; Centocor Ortho Biotech: Consultant or Advisor; Spectrum Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; Allergan: Consultant or Advisor; Endo Pharmaceuticals: Consultant or Advisor; MDx Health: Consultant or Advisor; Dendreon: Consultant or Advisor, Scientific Study or Trial; Photocure Inc: Scientific Study or Trial, Consultant or Advisor; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Takeda Inc: Consultant or Advisor
Cheryl Taylore Lee, MD: Adolor: Health Publishing; Pfizer: Scientific Study or Trial; Tengion, Inc: Consultant or Advisor, Scientific Study or Trial; Endo Pharmaceuticals: Scientific Study or Trial; Inverness: Consultant or Advisor; Photocure: Health Publishing; Allergan: Health Publishing, Consultant or Advisor; Archimedes: Consultant or Advisor; CVI: Consultant or Advisor
Alana Maeve Murphy, MD: Nothing to disclose
Charles Rye Pound, MD: Nothing to disclose
Jay I. Sandlow, MD: Nothing to disclose

Education Council Disclosures
Timothy Charles Brand, M.D.: Nothing to disclose             
Peter Robert Carroll, MD MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; AUA Update: Leadership Position        ; Genomic Health: Scientific Study or Trial            
Sam S. Chang, MD: astellas: Consultant or Advisor; NIH: Scientific Study or Trial; Cold Genesys, Inc: Scientific Study or Trial;                 GLG: Consultant or Advisor; Bayer: Consultant or Advisor            
Pat Fox Fulgham, MD: Urology Clinics of North Texas: Investment Interest
Matthew Thomas Gettman, M.D.: Nothing to disclose                   
Christina Giffin (OE Staff): Nothing to disclose  
Inderbir Singh Gill ,M.D., M.Ch.: Hansen Medical: Investment Interest; EDAP: Consultant or Advisor; EDAP: Consultant or Advisor; Mimic: Consultant or Advisor
Misop Han, MD: Nothing to disclose      
David Alan Hatch ,M.D.: Pfizer: Scientific Study or Trial  
Douglas A. Husmann MD: Nothing to disclose                    
Mark L. Jordan, M.D., F.A.C.S: Nothing to disclose           
Louis Koncz ,PA-C: American Medical Systems: Meeting Participant or Lecturer
Tracey Lynn Krupski, MD: Nothing to disclose                     
Cheryl Taylore Lee, MD: Endo Pharmaceuticals: Scientific Study or Trial 
Yair Lotan, M.D.: abbott: Scientific Study or Trial; Danone: Consultant or Advisor, Scientific Study or Trial; Cepheid: Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor; Biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; Photocure: Scientific Study or Trial               
Jill A. Macoska PhD: Nothing to disclose                 
Manoj Monga, MD, FACS: Fortec: Other; endourology society: Leadership Position
Victor William Nitti, MD (OE Staff): Serenity Pharmeuticals: Investment Interest            
Gail S. Prins PhD: Nothing to disclose                     
Lee Richstone, M.D.: Nothing to disclose                              
Karl-Dietrich Sievert, M.D., Ph.D.: AMS: Meeting Participant or Lecturer; Karl Storz: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial       ; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer            
Joseph A. Smith Jr.,M.D.: Nothing to disclose    
Sean Patrick Stroup: Intuitive Surgical: Meeting Participant or Lecturer; NeoTract: Meeting Participant or Lecturer
Edouard John Trabulsi, M.D.: Nothing to disclose   

Accreditation

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Non-physician Health Professionals

The AUA is not accredited to offer credit for non-physician health professionals. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-Label or Unapproved Use of Drugs or Devices

It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.